Atlanta—After hearing the latest findings from four large clinical trials assessing the effectiveness of high-dose chemotherapy (HDC) accompanied by bone marrow or stem cell transplantation, experts remain divided on the merits of this approach for treating advanced breast cancer.
Because of intense public interest in the approach, summaries of the interim results from the studies, scheduled to be presented at the annual meeting of the American Society for Clinical Oncology (ASCO), had been posted in April on the group's Web site (http://www.asco.org). The studies' preliminary findings suggested that HDC offers at least equivalent overall survival compared with conventional chemotherapy, but only one of the four, a South African study, demonstrated clear benefit (JAMA. 1999;281:1576-1578).
Stephenson J. Opinions Divided on High-Dose Chemotherapy for Breast Cancer. JAMA. 1999;282(2):119. doi:10.1001/jama.282.2.119-JMN0714-2-1